

Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

Condition Update

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for the condition update of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories. None of these individuals or organizations are responsible for the final contents of ICER's report or should be assumed to support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- AbbVie, Inc.
- Academy of Managed Care Pharmacy
- Aetna, Inc.
- Anthem, Inc.
- American Academy of Dermatology
- Amgen, Inc.
- Blue Shield of California
- California Department of Health Care Services
- Celgene Corp.
- Cigna, Inc.
- Eli Lilly and Co.
- Global Healthy Living Foundation
- Health Net, Inc.
- Janssen Biotech, Inc.
- Merck and Co.
- National Psoriasis Foundation
- Novartis AG
- Ortho Dermatologics (a division of Valeant Pharmaceuticals)
- Premera Blue Cross
- Sun Pharma
- UCB, Inc.
- UnitedHealthcare Services, Inc.